EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Intravenous metronidazole‐, levofloxacin‐containing triple therapy for treating patients with Helicobacter pylori ‐related active peptic ulcer complications: A pilot study

Wei Zhang, Qian Gui, Jinnan Chen, Dazhong Yu, Wenyu Su, Changqing Zhu, Xiao Liang, Hong Lu iD

Helicobacter · 2023

DOI: 10.1111/hel.12946 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Helicobacter, 2023. Verfasst von Wei Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease, NHC Key Laboratory of Digestive Diseases, Renji Hospital, Shang…. Hauptthemen laut MEDLINE: Helicobacter Infections, Helicobacter pylori, Peptic Ulcer. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: the National Natural Science Foundation of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The aim of this pilot study was to evaluate the efficacy and safety of intravenous use esomeprazole, metronidazole, and/or levofloxacin in the treatment of Helicobacter pylori ( H. pylori )‐associated peptic ulcer complications.

Methods

Inpatients with peptic ulcer complications who were not able to take oral medicine were randomly assigned to three groups: triple therapy (esomeprazole, levofloxacin, metronidazole) and dual therapy (esomeprazole, levofloxacin/metronidazole) for 7 days. After intravenous treatment, all patients received open‐label oral esomeprazole 20 mg bid for another 1 month. All subjects were followed up for gastroscopy at the seventh day of intravenous treatment to confirm the ulcer healing and 13 C‐urea breath test to confirm successful H. pylori eradication 4–6 weeks after completion of oral esomeprazole therapy.

Results

The H. pylori eradication rate of both LEV‐dual therapy (33.3%, 95% CI: 9.7%–70.0%) and MTZ‐dual therapy (50%, 95% CI: 21.5%–78.5%) was significantly lower than that of triple therapy (95%, 95% CI: 71.1%–97.4%) ( p = .003, .016). There were no significant differences in the adverse effects among all treatment groups, and the adverse effects were rare.

Conclusions

The intravenous triple regimen, consisting of proton‐pump inhibitor, metronidazole, and levofloxacin, could be considered in patients of H. pylori ‐associated peptic ulcer complications if oral medicine cannot be provided.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter InfectionsHelicobacter pyloriPeptic UlcerHumansAmoxicillinAnti-Bacterial AgentsDrug Therapy, CombinationEsomeprazoleLevofloxacinMetronidazolePilot Projects

Stichwörter der Autor:innen

Helicobacter pyloriintravenous therapeuticslevofloxacinmetronidazole

Substanzen

AmoxicillinAnti-Bacterial AgentsEsomeprazoleLevofloxacinMetronidazole

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease, NHC Key Laboratory of Digestive Diseases, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Emergency Medicine, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

ORCID-Profile: Hong Lu

Förderung

  • the National Natural Science Foundation of China
  • National Natural Science Foundation of China

Zitieren

APA

Zhang, W., Gui, Q., Chen, J., Yu, D., Su, W., Zhu, C., Liang, X., & Lu, H. (2023). Intravenous metronidazole‐, levofloxacin‐containing triple therapy for treating patients with Helicobacter pylori ‐related active peptic ulcer complications: A pilot study. Helicobacter. https://doi.org/10.1111/hel.12946

Vancouver

Zhang W, Gui Q, Chen J, Yu D, Su W, Zhu C, et al. Intravenous metronidazole‐, levofloxacin‐containing triple therapy for treating patients with Helicobacter pylori ‐related active peptic ulcer complications: A pilot study. Helicobacter. 2023. doi:10.1111/hel.12946

BibTeX
@article{Zhang2023,
  author = {Zhang, Wei and Gui, Qian and Chen, Jinnan and Yu, Dazhong and Su, Wenyu and Zhu, Changqing and Liang, Xiao and Lu, Hong},
  title = {Intravenous metronidazole‐, levofloxacin‐containing triple therapy for treating patients with Helicobacter pylori ‐related active peptic ulcer complications: A pilot study},
  journal = {Helicobacter},
  year = {2023},
  doi = {10.1111/hel.12946}
}
Kostenlos starten →